The most recent formulation for cystic fibrosis combines ivacaftor with another folding corrector, elexacaftor, and a channel potentiator, tezacaftor, and has shown efficacy toward CFTR mutants found in over 90% of cystic fibrosis patients (112, 113). The gene discussed is CFTR; the disease is cystic fibrosis.